TGF-β Signaling Is Often Attenuated during Hepatotumorigenesis, but Is Retained for the Malignancy of Hepatocellular Carcinoma Cells

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Mu, Xiaoxin ^a,b   Lin, Shu ^b   Yang, Junhua ^b   Chen, Chen ^a   Chen, Yun ^a   Herzig, Maryanne C ^b   Washburn, Kenneth ^c   Halff, Glenn A ^c   Walter, Christi A ^b,c,d   Sun, Beicheng ^a   Sun, Lu Zhe ^b,c  

^a THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^d SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SMAD PROTEIN; SMAD3 PROTEIN; SMAD4 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA RECEPTOR; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER TISSUE; CARCINOMA CELL; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; METASTASIS POTENTIAL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL ADHESION; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; LIVER NEOPLASMS; MICE; NEOPLASM METASTASIS; PROTEIN-SERINE-THREONINE KINASES; PTEN PHOSPHOHYDROLASE; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 84877955035     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063436     Document Type: Article

References (43)

1. Jemal A, Bray F, (2011) Center MM, Ferlay J, Ward E, et al (2011) Global cancer statistics. CA Cancer J Clin 61: 69-90.
2. Massague J, (2008) TGFbeta in Cancer. Cell 134: 215-30.
3. Siegel PM, Massague J, (2003) Cytostatic and apoptotic actions of TGF-beta in homeostasis and cancer. Nat Rev Cancer 3: 807-21.
4. Massague J, (2004) G1 cell-cycle control and cancer. Nature 432: 298-306.
5. Moustakas A, Heldin CH, (2005) Non-Smad TGF-beta signals. J Cell Sci 118: 3573-84.
6. Bedossa P, Peltier E, Terris B, Franco D, Poynard T, (1995) Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 21: 760-6.
7. Bissell DM, Wang SS, Jarnagin WR, Roll FJ, (1995) Cell-specific expression of transforming growth factor-beta in rat liver. Evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 96: 447-55.
8. Fausto N, Laird AD, Webber EM, (1995) Liver regeneration. 2. Role of growth factors and cytokines in hepatic regeneration. FASEB J 9: 1527-36.
9. Ito N, Kawata S, Tamura S, Shirai Y, Kiso S, et al. (1995) Positive correlation of plasma transforming growth factor-beta 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett 89: 45-8.
10. Shirai Y, Kawata S, Tamura S, Ito N, Tsushima H, et al. (1994) Plasma transforming growth factor-beta 1 in patients with hepatocellular carcinoma. Comparison with chronic liver diseases. Cancer 73: 2275-9.
11. Kawate S, Ohwada S, Hamada K, Koyama T, Takenoshita S, et al. (2001) Mutational analysis of the Smad6 and Smad7 genes in hepatocellular carcinoma. Int J Mol Med 8: 49-52.
12. Kawate S, Takenoshita S, Ohwada S, Mogi A, Fukusato T, et al. (1999) Mutation analysis of transforming growth factor beta type II receptor, Smad2, and Smad4 in hepatocellular carcinoma. Int J Oncol 1999 Jan 14: 127-31.
13. Yakicier MC, Irmak MB, Romano A, Kew M, Ozturk M, (1999) Smad2 and Smad4 gene mutations in hepatocellular carcinoma. Oncogene 18: 4879-83.
14. Levy L, Hill CS, (2006) Alterations in components of the TGF-beta superfamily signaling pathways in human cancer. Cytokine Growth Factor Rev 17: 41-58.
15. Furuta K, Misao S, Takahashi K, Tagaya T, Fukuzawa Y, et al. (1999) Gene mutation of transforming growth factor beta1 type II receptor in hepatocellular carcinoma. Int J Cancer 81: 851-3.
16. Morris SM, Baek JY, Koszarek A, Kanngurn S, Knoblaugh SE, et al. (2012) Transforming growth factor-beta signaling promotes hepatocarcinogenesis induced by p53 loss. Hepatology 55: 121-31.
17. Zhou ZQ, Manguino D, Kewitt K, Intano GW, Mcmahan CA, et al. (2001) Spontaneous hepatocellular carcinoma is reduced in transgenic mice overexpressing human O6- methylguanine-DNA methyltransferase. Proc Natl Acad Sci U S A 98: 12566-71.
18. Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee WC, Pontz T, et al. (2003) Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFbeta receptor kinase (TbetaRI). Bioorg Med Chem Lett 13: 4355-9.
19. Lei X, Bandyopadhyay A, Le T, Sun L, (2002) Autocrine TGFbeta supports growth and survival of human breast cancer MDA-MB-231 cells. Oncogene 21: 7514-23.
20. Zawel L, Dai JL, Buckhaults P, Zhou S, Kinzler KW, et al. (1998) Human Smad3 and Smad4 are sequence-specific transcription activators. Mol Cell 1: 611-7.
21. Chen C, Wang XF, Sun L, (1997) Expression of transforming growth factor beta (TGFbeta) type III receptor restores autocrine TGFbeta1 activity in human breast cancer MCF-7 cells. J Biol Chem 272: 12862-7.
22. Lin S, Yu L, Yang J, Liu Z, Karia B, et al. (2011) Mutant p53 disrupts role of ShcA protein in balancing Smad protein-dependent and-independent signaling activity of transforming growth factor-beta (TGF-beta). J Biol Chem 286: 44023-34.
23. Li L, Price JE, Fan D, Zhang RD, Bucana CD, et al. (1989) Correlation of growth capacity of human tumor cells in hard agarose with their in vivo proliferative capacity at specific metastatic sites. J Natl Cancer Inst 81: 1406-12.
24. Mishra S, Tang Y, Wang L, deGraffenried L, Yeh IT, et al. (2011) Blockade of transforming growth factor-beta (TGFbeta) signaling inhibits osteoblastic tumorigenesis by a novel human prostate cancer cell line. Prostate 71: 1441-54.
25. Wurmbach E, Chen YB, Khitrov G, Zhang W, Roayaie S, et al. (2007) Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 45: 938-47.
26. Bierie B, Moses HL, (2006) TGF-beta and cancer. Cytokine Growth Factor Rev 17: 29-40.
27. Coulouarn C, Factor VM, Thorgeirsson SS, (2008) Transforming growth factor-beta gene expression signature in mouse hepatocytes predicts clinical outcome in human cancer. Hepatology 47: 2059-67.
28. Gourley C, Paige AJ, Taylor KJ, Scott D, Francis NJ, et al. (2005) WWOX mRNA expression profile in epithelial ovarian cancer supports the role of WWOX variant 1 as a tumour suppressor, although the role of variant 4 remains unclear. Int J Oncol 26: 1681-9.
29. Fridman R, Giaccone G, Kanemoto T, Martin GR, Gazdar AF, et al. (1990) Reconstituted basement membrane (matrigel) and laminin can enhance the tumorigenicity and the drug resistance of small cell lung cancer cell lines. Proc Natl Acad Sci U S A 87: 6698-702.
30. Muraoka-Cook RS, Shin I, Yi JY, Easterly E, Barcellos-Hoff MH, et al. (2006) Activated type I TGFbeta receptor kinase enhances the survival of mammary epithelial cells and accelerates tumor progression. Oncogene 25: 3408-23.
31. Lei X, Yang J, Nichols RW, Sun LZ, (2007) Abrogation of TGFbeta signaling induces apoptosis through the modulation of MAP kinase pathways in breast cancer cells. Exp Cell Res 313: 1687-95.
32. Hannon GJ, Beach D, (1994) p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest. Nature 371: 257-61.
33. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, et al. (1995) Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci U S A 92: 5545-9.
34. Fabregat I, Roncero C, Fernandez M, (2007) Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int 27: 155-62.
35. Li DM, Sun H, (1997) TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57: 2124-9.
36. Matsuzaki K, (2011) Smad phosphoisoform signaling specificity: the right place at the right time. Carcinogenesis 32: 1578-88.
37. Kiss A, Wang NJ, Xie JP, Thorgeirsson SS, (1997) Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 3: 1059-66.
38. Murata M, Matsuzaki K, Yoshida K, Sekimoto G, Tahashi Y, et al. (2009) Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology. 49: 1203-17.
39. Matsuzaki K, Murata M, Yoshida K, Sekimoto G, Uemura Y, et al. (2007) Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 46: 48-57.
40. Senturk S, Mumcuoglu M, Gursoy-Yuzugullu O, Cingoz B, Akcali KC, et al. (2010) Transforming growth factor-beta induces senescence in hepatocellular carcinoma cells and inhibits tumor growth. Hepatology 52: 966-74.
41. Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, et al. (2000) Autocrine stimulatory mechanism by transforming growth factor beta in human hepatocellular carcinoma. Cancer Res 60: 1394-402.
42. Matsuzaki K, Date M, Furukawa F, Tahashi Y, Matsushita M, et al. (2000) Regulatory mechanisms for transforming growth factor beta as an autocrine inhibitor in human hepatocellular carcinoma: implications for roles of smads in its growth. Hepatology 32: 218-27.
43. Inagaki M, Moustakas A, Lin HY, Lodish HF, Carr BI, (1993) Growth inhibition by transforming growth factor beta (TGF-beta) type I is restored in TGF-beta-resistant hepatoma cells after expression of TGF-beta receptor type II cDNA. Proc Natl Acad Sci U S A 90: 5359-63.